foxo4-dri human trial senolytic Buy 10mg – Senescence Pathway Research Peptide FOXO4-DRI alleviates age-related testosterone secretion
FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI 10mg vial Description RCpeptides FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC
Pay in 4 interest-free payments of $5.41 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18



